Biocon Biologics believes in harnessing the power of strategic partnerships and collaborations to pursue the kind innovation needed to attain the dream of ensuring high quality healthcare for all. While we have developed in-house R&D strengths to deliver cutting-edge science, we have also built strategic global partnerships of a symbiotic nature that allow us to share risks, lower costs, maximize our efficiencies, expedite development and expand our reach.
Our long-standing global partnership with Viatris (formerly Mylan) started in 2009 to co-develop a portfolio of biosimilar antibodies and other recombinant proteins, and was expanded to include insulin analogs in 2013. Viatris and Biocon Biologics have an exclusive collaboration for the development, manufacturing and commercialization of a broad portfolio of biosimilars and insulin analogs. Today, we have one of the most extensive biosimilars pipelines under global development. The partnership has started to deliver returns for both partners with several molecules from the early wave of biosimilars co-developed with Mylan having been commercialized in developed markets like U.S. and Europe, as well as, key emerging markets.
Viatris has exclusive commercialization rights in the U.S., Canada, Australia, New Zealand, the European Union and European Free Trade Association countries. Biocon Biologics has exclusive commercialization rights for Japan and certain emerging markets. Viatris and Biocon Biologics have co-exclusive commercialization rights in the rest of the world. The Viatris collaboration is a cost-share and profit-share model.
We partnered with Sandoz, a division of Novartis, in 2018 for the development of next-generation biosimilars portfolio for immunology and oncology. This synergistic partnership is providing us an opportunity to scale up our capabilities for an ‘end to end’ play in the global biosimilars space. Our global partnership with Sandoz prepares us for the next wave of biosimilar opportunities that are likely to open up. The Sandoz partnership is structured based on an equal economic share with Sandoz having commercialization rights in developed markets and the responsibility for development and manufacturing is shared between the partners.
Serum Institute Life Sciences
The strategic alliance between Biocon Biologics and Serum Institute Life Sciences Private Limited (SILS), a subsidiary of Serum Institute of India Pvt. Ltd., complements and combines the two companies’ capabilities and capacities in vaccines and biologics, with the objective of addressing inequitable access both in emerging and developed markets for life saving vaccines and biologics. Under the terms of the agreement, BBL will offer ~15% stake to SILS, at a post-money valuation of ~$4.9 billion, for which it will get committed access to a 100 million doses of vaccines each year for 15 years with commercialization rights of the SILS vaccine portfolio (including COVID-19 vaccines) for global markets. In addition to vaccines, the strategic alliance will also develop antibodies targeting several infectious diseases like Dengue, HIV etc.
Biocon Biologics has obtained exclusive license from Adagio Therapeutics to manufacture and commercialize an antibody treatment based on the U.S. company’s novel monoclonal antibody, ADG20, for India and select emerging markets. ADG20, which targets the spike protein of SARS-CoV-2 and related coronaviruses, is in global clinical development by Adagio as a single agent for both the treatment and prevention of COVID-19, the disease caused by the SARS-CoV-2 virus, its variants, as well as future variants that may emerge. With its potential to address resistant variants, including the Delta variant, and its ability to be administered easily as a single, intramuscular injection in the outpatient setting, ADG20 is uniquely poised to address the current need for an effective, safe and convenient therapy for COVID-19. This partnership with Adagio represents the companies’ shared mission to provide affordable access to a best-in-class antibody therapy for people affected by SARS-CoV-2.
Biocon Biologics’ global collaboration with Voluntis, a leader in digital therapeutics, is aimed at developing and distributing innovative digital therapeutics supporting people with diabetes on biologics therapy. The licensing agreement with Voluntis will make Biocon Biologics one of the first insulins companies to offer a U.S. Food and Drug Administration-cleared and CE-marked, highly validated digital therapeutic product, Insulia®, to Type 2 diabetes patients, across several markets in the world. Insulia® is the first digital therapeutic with regulatory clearance to provide automated titration recommendations for all types of basal insulins. It allows people with diabetes to self-manage their condition and healthcare teams to remotely monitor progress.